Transforming growth factor beta receptor type 1 and type 2 (TGFBR1/2)

The Transforming growth factor beta (TGF-beta) receptor complex, primarily composed of the type 1 (TGFBR1) and type 2 (TGFBR2) subunits, is a pivotal signaling hub that regulates a wide array of cellular processes including growth, differentiation, and immune homeostasis [UniProt P36897, P37173]. Upon binding of TGF-beta ligands, the receptors form a heterotetrameric complex where TGFBR2 phosphorylates and activates TGFBR1, subsequently triggering the canonical SMAD signaling pathway or various non-canonical pathways. In the tumor microenvironment, these receptors on immune cells (such as T cells and myeloid cells) mediate potent immunosuppressive effects, while their activation on stromal fibroblasts promotes the production of extracellular matrix and facilitates the epithelial-mesenchymal transition (EMT) [PubMed: 30635239]. This dual action on both the immune system and the structural stroma makes the receptor complex a critical driver of tumor progression and resistance to immunotherapy. Consequently, the TGF-beta receptor complex has become a major therapeutic target in oncology and fibrotic diseases, with the goal of restoring anti-tumor immunity and inhibiting tissue remodeling. However, drug development is complicated by the pleiotropic nature of TGF-beta signaling, leading to potential safety concerns such as cardiotoxicity and the development of benign or malignant skin lesions [PubMed: 21421917, 25834455].

Other names

TGF-beta receptor type I and IITGF-beta receptor complexTbetaRI/TbetaRIIALK5/TGFBR2TGF-beta receptor 1 and 2

Small molecule inhibitors typically target the intracellular kinase domain of TGFBR1 (ALK5) to prevent the phosphorylation of SMAD2/3, thereby blocking downstream canonical signaling [PubMed: 25834455]. Monoclonal antibodies or trap proteins may also block the extracellular binding of TGF-beta ligands to the receptor complex to prevent activation [PubMed: 30635239].